Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus Maintenance Dosing in Kaposiform Hemangioendothelioma
NCT05324384Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in kaposiform hemangioendothelioma (KHE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Changes in KHE volume at 12 months. Started Apr 2022; status: recruiting.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)
Beyond the preview
Go deeper on NCT05324384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324384.